DAMONA’s pipeline is focused on brain receptor modulation, including positive allosteric modulators (PAM) at the α5-GABA-A receptor. Our lead program, DPX-101, has additional life cycle opportunities for preventing depression relapse, delaying Alzheimer’s disease onset, and preventing and/or reversing nerve cell damage.